NeuroX1, an Austin-based startup announced on March 3, 2023, that it has raised $500,000 in seed funding. The funding round was led by Drive Capital, a private investment firm that focuses on building long-term, sustainable businesses.
NeuroX1 is a computational drug design company that uses artificial intelligence (AI) to develop new compounds for neurological and neurodegenerative diseases. The company’s proprietary platform, Chiron, is a generative chemistry platform that identifies drivers of these diseases and designs novel compounds to treat them.
Founded in 2021, NeuroX1 is focused on developing drugs for rare pediatric neurological diseases, as well as Alzheimer’s and Parkinson’s.
With this new funding, the company plans to expand its team and accelerate its drug discovery efforts.
The founders of NeuroX1, Conner Myers, Lucas Myers, and Maxwell Dordevic, are excited about the opportunity to bring new drugs to market using their AI-powered platform. The company’s specialties include biotechnology, generative drug discovery, and neuroscience, among others.
NeuroX1 aims to address the unmet medical needs of patients suffering from neurological and neurodegenerative diseases by developing new treatments and therapies. The company’s cutting-edge technology has the potential to revolutionize drug discovery and improve the lives of millions of people worldwide.
As the company continues to grow, it plans to collaborate with leading research institutions and pharmaceutical companies to bring its innovations to market.
